Thermo Fisher Scientific moves to broaden its presence in Asia’s fast‑growing biologics market, adding a new Bioprocess Design Center in Hyderabad and expanding existing centres in Incheon and Singapore.
The network is pitched to speed development and scale‑up for vaccines, biologics, and cell and gene therapies across the region. Thermo Fisher says the goal is local expertise, shorter timelines, and more flexible manufacturing options. The plan is regionally focused.
The three sites form a linked hub for process design, simulation, and training. Hyderabad’s centre sits in Genome Valley, developed with the Government of Telangana, and offers spaces to co‑create and test bioprocesses using single‑use and hybrid systems.
Incheon’s upgrade adds advanced materials and enhanced lab capabilities, while the Singapore site provides bench‑to‑pilot scale access and expert‑led training. Each location supports early to commercial stages.
Tri‑hub model targets speed and scale
Across the network, Thermo Fisher points to faster process development and more predictable tech transfer. The centres aim to cut risk in procurement and commissioning by standardizing equipment, workflows, and training at source.
Hyderabad’s facility, part of a broader innovation campus, was inaugurated on Nov. 25, 2025, adding capacity ahead of the formal expansion notice. That timing underscores demand for hands‑on support for regional manufacturers.
“Asia continues to play an increasingly important role in advancing innovation,” said Daniella Cramp, Senior Vice President and President, BioProduction. The expansion brings equipment, talent, and testing capacity closer to developers that need them. The approach also leans on single‑use technologies to keep changeover times short. Thermo Fisher frames the package as a practical answer to capacity constraints.
Regional policy has set the stage. Telangana has courted global bioprocess players through Genome Valley and related partnerships, while Korea and Singapore continue to invest in workforce and lab infrastructure. The centres also tie into Thermo Fisher’s wider portfolio in analytics and process control, which underpins validation and regulatory submissions.
“Through advanced manufacturing, strategic partnerships and targeted regional investments, we are redefining what is possible in biologics production,” said Tony Acciarito, President, Asia Pacific and Middle East, Africa.
The tri‑hub design lowers barriers between pilot and commercial stages. Standardized platforms can shorten vendor selection and reduce commissioning surprises. Local training arms help operators hit quality targets earlier, supporting smoother validation runs.
Developers active in Asia may see shorter tech‑transfer timelines and more predictable procurement. The test will be how quickly projects move from first runs to stable output under this shared model.